There have been quite a few successful published programmes for pancreatic surgery as well as published ERAS guidelines. But less is known about the economic benefits of these programmes.
What this paper adds:
This was a Canadian retrospective cost minimization analysis of patients undergoing pancreaticoduodenectomy with an ERAS programme versus standard care. Despite only a small reduction in total length of stay (10 vs 11 days, p=0.003), there was a pretty impressive cost saving of over 13,000 Canadian dollars per patient (including readmissions, $16,627 vs $29,872, p=0.016). The main areas of cost savings were through reducing unnecessary laboratory tests and imaging investigations. Showing nicely that it is not just reducing bed-days that saves money.
Enhanced recovery in liver surgery decreases postoperative outpatient use of opioids. Lillemoe HA et al (2019) Enhanced recovery in liver surgery decreases postoperative outpatient use of opioids. Surgery. May…